POLLUX & amp; CASTOR Studies for Relapsed or Refractory Multiple Myeloma
Mark Wildgust, Vice President of Global Medical Affairs for Janssen Oncology gives an overview of the POLLUX/CASTOR studies, which looked at daratumumab in combination with lenalidomide plus dexametha...
Author: ASCO2017
Added: 06/15/2017 (Source: Oncology Tube)
Source: Oncology Tube - June 15, 2017 Category: Cancer & Oncology Source Type: podcasts
REVLIMID (Lenalidomide) Maintenance Therapy Approved for Multiple Myeloma Patients
Philip McCarthy, MD, Director of the Blood and Marrow Transplant Center at Roswell Park Cancer Institute in Buffalo, NY, shares benefits of lenalidomide maintenance therapy for multiple myeloma patien...
Author: roswellpark
Added: 03/16/2017 (Source: Oncology Tube)
Source: Oncology Tube - March 16, 2017 Category: Cancer & Oncology Source Type: podcasts
Inleiding tot de ASH bespreking over Ibrutinib monotherapie
In dit fragment word een inleiding gegeven. Er worst gesproken over lange termijn effecten van Ibrutinib monotherapie behandeling. Ook wordt het effect van Lenalidomide behandeling na dat de patint ...
Author: PatientPowerEU
Added: 02/20/2017 (Source: Oncology Tube)
Source: Oncology Tube - February 20, 2017 Category: Cancer & Oncology Source Type: podcasts
How do Revlimid and dexamethasone work together against myeloma?
In this weeks video, Dr. Brian Durie addresses a patients concern about continued use of dexamethasone with Rev/dex combination therapy.<br /><br />BOTTOM LINE: <br /><br />Rev/dex is great for initial therapy, but...
Author: MultipleMyeloma
Added: 11/22/2016 (Source: Oncology Tube)
Source: Oncology Tube - November 22, 2016 Category: Cancer & Oncology Source Type: podcasts
Can Reducing a Dose of Myeloma Maintenance Therapy Increase Risk of Relapse?
In this Ask the Expert segment, Terry is concerned about his mother’s treatment and side effects. He wants to know if a reduction of the dose of Revlimid and dexamethasone will make the treatment less...
Author: P2Professional
Added: 06/24/2016 (Source: Oncology Tube)
Source: Oncology Tube - June 24, 2016 Category: Cancer & Oncology Source Type: podcasts
Can Reducing a Dose of Myeloma Maintenance Therapy Increase Risk of Relapse?
In this Ask the Expert segment, Terry is concerned about his mother’s treatment and side effects. He wants to know if a reduction of the dose of Revlimid and dexamethasone will make the treatment less...
Author: patientpower
Added: 06/24/2016 (Source: Oncology Tube)
Source: Oncology Tube - June 24, 2016 Category: Cancer & Oncology Source Type: podcasts
EHA 2016: When will the daratumumab triplet combination be approved for multiple myeloma?
Antonio Palumbo, MD from the University of Turin, Turin, Italy talks about when daratumumab will be available in combination with bortezomib and dexamethasone or lenalidomide and dexamethasone. Daratu...
Author: VJHemOnc
Added: 06/24/2016 (Source: Oncology Tube)
Source: Oncology Tube - June 24, 2016 Category: Cancer & Oncology Source Type: podcasts
EHA 2016: The benefits of lenalidomide and dexamethasone
Katja Weisel, MD from University Hospital Tuebingen, Tuebingen, Germany discusses the slowly progressing myeloma and outlines how there are clear benefits to receiving lenalidomide and dexamethasone b...
Author: VJHemOnc
Added: 06/24/2016 (Source: Oncology Tube)
Source: Oncology Tube - June 24, 2016 Category: Cancer & Oncology Source Type: podcasts
EHA 2016: Results of Phase III POLLUX trial on daratumumab in multiple myeloma
Noopur Raje, MD from the Massachusetts General Hospital, Boston, MA gives an overview of the Phase III POLLUX trial on (NCT02076009) on combining daratumumab with lenalidomide and dexamethasone vs len...
Author: VJHemOnc
Added: 06/21/2016 (Source: Oncology Tube)
Source: Oncology Tube - June 21, 2016 Category: Cancer & Oncology Source Type: podcasts
How immunomodulatory drugs have reinforced the value of the immune system in multiple myeloma
Jesús San Miguel, MD, PhD, from the University of Navarra, Navarra, Spain gives an overview of immunomodulatory drugs (IMiDs) thalidomide, lenalidomide and pomalidomide for multiple myeloma (MM). Acco...
Author: VJHemOnc
Added: 05/24/2016 (Source: Oncology Tube)
Source: Oncology Tube - May 24, 2016 Category: Cancer & Oncology Source Type: podcasts
The FORTE clinical trial of carfilzomib in multiple myeloma
Gareth Morgan, MD, FRCP, FRCPath, PhD from the University of Arkansas for Medical Sciences, Arkansas, AR discusses the results of clinical trial of carfilzomib, lenalidomide, cyclophosphamide and dexa...
Author: VJHemOnc
Added: 02/29/2016 (Source: Oncology Tube)
Source: Oncology Tube - February 29, 2016 Category: Cancer & Oncology Source Type: podcasts
Overview of the Tourmaline-MM1 study in relapsed/refractory multiple myeloma
Paul Richardson, MD from the Dana-Farber Cancer Institute Medical Oncology, Boston, MA provides an overview of the Tourmaline-MM1 study of ixazomib in combination with lenalidomide and dexamethasone i...
Author: VJHemOnc
Added: 02/11/2016 (Source: Oncology Tube)
Source: Oncology Tube - February 11, 2016 Category: Cancer & Oncology Source Type: podcasts
Transplant vs bortezomib and LEN/DEX in multiple myeloma
Rafael Fonseca, MD from the Mayo Clinic, Scottsdale, AZ provides an overview of a clinical trial (IFM 2013-04) of bortezomib plus lenalidomide and dexamethasone (LEN/DEX) as the primary treatment for ...
Author: VJHemOnc
Added: 02/10/2016 (Source: Oncology Tube)
Source: Oncology Tube - February 10, 2016 Category: Cancer & Oncology Source Type: podcasts
Update on ELOQUENT-2: Phase 3 trial of elotuzumab in relapsed/refractory multiple myeloma
Sagar Lonial, MD from Emory University Winship Cancer Institute, Atlanta, GA gives an overview of the ELOQUENT-2 clinical trial of lenalidomide/dexamethasone with/without elotuzumab in patients with r...
Author: VJHemOnc
Added: 02/09/2016 (Source: Oncology Tube)
Source: Oncology Tube - February 9, 2016 Category: Cancer & Oncology Source Type: podcasts
